MedTrace Logo

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-02-09

No results posted yet for this study

Summary

To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.

Conditions

Interventions

DRUG

Lenvatinib Plus Tislelizumab

Lenvatinib is 12mg/d for body weight \>= 60kg, 8mg/d for body weight \<60kg, once daily orally, once a day, after meals (take at the same time every day as much as possible); Tislelizumab is administered intravenously at a dose of 200mg/q3w.

DEVICE

Transarterial Chemoembolization(TACE)

A catheter is inserted through a small incision in the groin and guided to the hepatic artery, which supplies blood to the liver;A contrast dye is injected through the catheter to help visualize the blood vessels in the liver; A mixture of chemotherapy drugs and an embolic agent (such as small beads or gel foam) is injected through the catheter and into the artery that feeds the tumor;The embolic agent helps to block the blood flow to the tumor, which starves it of oxygen and nutrients; The chemotherapy drugs are then trapped in the tumor.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-04-15
Completion
2024-11-15
FDA Drug
Yes
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05842317 on ClinicalTrials.gov